T-cell depleting antibodies

Mechanism of Action - T-Cell Takedown

• Polyclonal (e.g., Antithymocyte Globulin) and monoclonal (e.g., Alemtuzumab) antibodies bind to a variety of antigens on the T-cell surface.
• This tagging marks the T-cell for destruction through:
  • Complement-Dependent Cytotoxicity (CDC): The antibody activates the complement system, leading to cell lysis.
  • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): NK cells and phagocytes recognize the antibody and destroy the T-cell.
• Alemtuzumab specifically targets the CD52 antigen.

⭐ First-dose reactions, like Cytokine Release Syndrome (CRS), can be severe. This is due to the initial massive activation and lysis of T-cells, releasing a flood of inflammatory cytokines.

Polyclonal Antibodies - The Broadside

• Agents: Anti-thymocyte Globulin (ATG) derived from horse or rabbit serum.
• Mechanism: A "broadside" attack. Binds to a wide array of T-cell surface antigens (CD2, CD3, CD4, etc.), triggering complement-dependent lysis and clearance by phagocytes. Causes profound T-cell depletion.
• Clinical Use:
  • Induction therapy for preventing rejection in solid organ transplants (especially kidney).
  • Treatment of severe, steroid-resistant acute rejection.
• Adverse Effects:
  • ⚠️ Cytokine Release Syndrome (CRS): Systemic inflammation (fever, rigors, hypotension) after the first dose due to massive cytokine release from lysed T-cells.
  • Serum Sickness: Type III hypersensitivity (fever, rash, arthralgia) days to weeks later.
  • Leukopenia, thrombocytopenia.
  • Increased risk of infection (CMV) & PTLD.

⭐ High-Yield: To manage expected Cytokine Release Syndrome, pre-medicate patients with corticosteroids, acetaminophen, and antihistamines before the first ATG infusion.

Monoclonal Antibodies - The CD52 Sniper

• Alemtuzumab: A humanized monoclonal antibody that targets the CD52 antigen.

  • Mechanism: Binds to CD52 on T-cells, B-cells, NK cells, monocytes, and macrophages. This triggers complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
  • Effect: Causes rapid, profound, and long-lasting depletion of lymphocytes.

• Primary Uses:

  • Relapsing-Remitting Multiple Sclerosis (MS).
  • Chronic Lymphocytic Leukemia (CLL).
  • Formerly used in transplant rejection.

• Major Adverse Effects:

  • Pancytopenia: Especially severe lymphopenia, requiring prophylaxis against opportunistic infections (e.g., PJP, Herpesviruses).
  • Infusion Reactions: Pre-medication is necessary.
  • Secondary Autoimmunity: Thyroid disease, ITP, nephropathies.

⭐ High-Yield: A major long-term complication is the development of secondary autoimmune diseases (e.g., Graves' disease, ITP), which can occur in up to 50% of patients months to years after treatment.

📌 Mnemonic: Alemtuzumab causes elemination of CD52 cells.

Adverse Effects - The Aftermath

• Cytokine Release Syndrome (CRS):
  • Systemic inflammation from rapid T-cell lysis.
  • Presents with fever, chills, rigors, headache, hypotension.
  • ⚠️ Most severe with the first dose.
• Increased Infection Risk:
  • High risk for opportunistic infections.
  • Key pathogens: CMV, PJP, BK virus.
  • Requires prophylactic antimicrobial therapy.
• Malignancy:
  • Increased risk of Post-Transplant Lymphoproliferative Disorder (PTLD), usually EBV-driven.
  • Skin cancers.
• Drug-Specific:
  • Alemtuzumab: Pancytopenia, autoimmune thyroiditis.

⭐ Muromonab-CD3 (OKT3) is notorious for causing a severe, potentially fatal CRS after the first dose, often called the "first-dose reaction."

High‑Yield Points - ⚡ Biggest Takeaways

• Alemtuzumab targets CD52 on most lymphocytes, used for MS and CLL; causes profound, prolonged lymphopenia.
• Muromonab-CD3 (OKT3) is a murine antibody against the T-cell CD3 receptor, causing rapid T-cell depletion.
• First dose of Muromonab often causes a severe cytokine release syndrome.
• Basiliximab and daclizumab are monoclonal antibodies targeting the IL-2 receptor (CD25).
• Primarily used for prophylaxis of acute rejection in renal transplantation.
• Major risks for all include increased susceptibility to infection and malignancy.